{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T09:37:00Z","timestamp":1786527420097,"version":"build-2736575974"},"reference-count":20,"publisher":"Walter de Gruyter GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_cclm-2026-0509_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Vancomycin is a glycopeptide antibiotic used to treat severe Gram-positive infections; its narrow therapeutic window makes therapeutic drug monitoring (TDM) critical. We report the development of a liquid chromatography-tandem mass spectrometry (LC-MS\/MS) candidate reference measurement procedure (RMP) to quantify vancomycin in human plasma and\u00a0serum.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2026-0509_abs_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Quantitative nuclear magnetic resonance (qNMR) spectroscopy was used to determine the absolute content of the reference material, ensuring direct traceability to the International System of Units (SI). Sample preparation used a\u00a0protein precipitation protocol followed by high dilution. LC-MS\/MS parameters, including selectivity, precision, accuracy, equivalence to the listed RMP, and measurement uncertainty (MU) were evaluated. MU determination was performed according to the guide to the expression of uncertainty in measurement (GUM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2026-0509_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The RMP was validated over a measuring interval of 0.690\u201358.7\u202f\u03bcmol\/L (1.00\u201385.0\u202f\u03bcg\/mL). Intermediate precision and repeatability were &lt;2.9\u202f% and &lt;2.1\u202f%, respectively. Direct comparison with the current JCTLM-listed RMP revealed an 18.3\u202f% downward shift in results. This bias was proven to be entirely attributable to the transition from activity-based to mass-based standardization. Expanded MU (k=2) ranged from 5.1\u202f% to 6.0\u202f% for single measurements and 2.1\u20133.1\u202f% for target value assignment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2026-0509_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This candidate RMP provides a superior metrological foundation for vancomycin quantification by establishing direct SI-traceability and a fully characterized uncertainty budget. While its implementation necessitates a re-evaluation of clinical decision thresholds, it significantly enhances the global standardization of TDM assays.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/cclm-2026-0509","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T08:57:36Z","timestamp":1786438656000},"source":"Crossref","is-referenced-by-count":0,"title":["A liquid chromatography-tandem mass spectrometry-based candidate reference measurement procedure for the quantification of vancomycin in human serum and plasma"],"prefix":"10.1515","author":[{"given":"Sandra","family":"Fleischer","sequence":"first","affiliation":[{"name":"Roche Diagnostics GmbH , Penzberg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Singh","sequence":"additional","affiliation":[{"name":"Roche Diagnostics GmbH , Penzberg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friederike","family":"Bauland","sequence":"additional","affiliation":[{"name":"Evidenze Germany GmbH , Essen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Geistanger","sequence":"additional","affiliation":[{"name":"Roche Diagnostics GmbH , Penzberg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Taibon","sequence":"additional","affiliation":[{"name":"Roche Diagnostics GmbH , Penzberg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elie","family":"Fux","sequence":"additional","affiliation":[{"name":"Roche Diagnostics GmbH , Penzberg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"2026081209035282989_j_cclm-2026-0509_ref_001","doi-asserted-by":"crossref","unstructured":"Alrasheed, MA, Alamer, KA, Ghonem, L, Alsuhibani, AA, Tawfik, YM, Alsultan, MM, et al.. Therapeutic drug monitoring of vancomycin: a retrospective cross-sectional study of blood draw timing and clinical outcomes. Medicine (Baltim) 2025;104:e42952. https:\/\/doi.org\/10.1097\/md.0000000000042952.","DOI":"10.1097\/MD.0000000000042952"},{"key":"2026081209035282989_j_cclm-2026-0509_ref_002","doi-asserted-by":"crossref","unstructured":"Cheng, X, Ma, J, Su, J. An overview of analytical methodologies for determination of vancomycin in human plasma. Molecules 2022;27:7319. https:\/\/doi.org\/10.3390\/molecules27217319.","DOI":"10.3390\/molecules27217319"},{"key":"2026081209035282989_j_cclm-2026-0509_ref_003","unstructured":"Vancomycin dosing and monitoring in adults. Australia: National Antimicrobial Utilisation Surveillance Program Communicable Disease Control Branch; 2019."},{"key":"2026081209035282989_j_cclm-2026-0509_ref_004","doi-asserted-by":"crossref","unstructured":"Rybak, MJ, Le, J, Lodise, TP, Levine, DP, Bradley, JS, Liu, C, et al.. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2020;77:835\u201364.","DOI":"10.1093\/ajhp\/zxaa036"},{"key":"2026081209035282989_j_cclm-2026-0509_ref_005","doi-asserted-by":"crossref","unstructured":"Legg, A, Devchand, F, Gwee, A, Sandaradura, I, Lai, T. Safe and effective use of vancomycin. Aust Prescr 2025;48:54\u20139. https:\/\/doi.org\/10.18773\/austprescr.2025.013.","DOI":"10.18773\/austprescr.2025.013"},{"key":"2026081209035282989_j_cclm-2026-0509_ref_006","doi-asserted-by":"crossref","unstructured":"K\u00f6nig, K, Kobold, U, Fink, G, Leinenbach, A, D\u00fclffer, T, Thiele, R, et al.. Quantification of vancomycin in human serum by LC-MS\/MS. Clin Chem Lab Med 2013;51:1761\u20139. https:\/\/doi.org\/10.1515\/cclm-2013-0142.","DOI":"10.1515\/cclm-2013-0142"},{"key":"2026081209035282989_j_cclm-2026-0509_ref_007","unstructured":"USP general chapter antibiotics\u00a0\u2013\u00a0microbial assays; 2025."},{"key":"2026081209035282989_j_cclm-2026-0509_ref_008","unstructured":"Food and Drug Administration. Pharmaceutical microbiology manual. Office of Regulatory Affairs; 2020."},{"key":"2026081209035282989_j_cclm-2026-0509_ref_009","unstructured":"International organization for standardization; 2020 ISO 17511:2020."},{"key":"2026081209035282989_j_cclm-2026-0509_ref_010","doi-asserted-by":"crossref","unstructured":"Fraser, CG. Desirable standards of performance for therapeutic drug monitoring. Clin Chem 1987;33:387\u20139. https:\/\/doi.org\/10.1093\/clinchem\/33.3.387.","DOI":"10.1093\/clinchem\/33.3.387"},{"key":"2026081209035282989_j_cclm-2026-0509_ref_011","unstructured":"Vancomycin injection. Xellia Pharmaceuticals; 2021."},{"key":"2026081209035282989_j_cclm-2026-0509_ref_012","doi-asserted-by":"crossref","unstructured":"Braga, F, Panteghini, M. The utility of measurement uncertainty in medical laboratories. Clin Chem Lab Med 2020;58:1407\u201313. https:\/\/doi.org\/10.1515\/cclm-2019-1336.","DOI":"10.1515\/cclm-2019-1336"},{"key":"2026081209035282989_j_cclm-2026-0509_ref_013","unstructured":"Richtlinie der Bundes\u00e4rztekammer zur Qualit\u00e4tssicherung laboratoriumsmedizinischer Untersuchungen. In: Bundes\u00e4rztekammer. Available from: https:\/\/www.bundesaerztekammer.de\/fileadmin\/user_upload\/BAEK\/Themen\/Qualitaetssicherung\/_Bek_BAEK_RiLi_QS_laboratoriumsmedizinischer_Untersuchungen.pdf."},{"key":"2026081209035282989_j_cclm-2026-0509_ref_014","doi-asserted-by":"crossref","unstructured":"Lynch, KL. CLSI C62-A: a new standard for clinical mass spectrometry. Clin Chem 2016;62:24\u20139. https:\/\/doi.org\/10.1373\/clinchem.2015.238626.","DOI":"10.1373\/clinchem.2015.238626"},{"key":"2026081209035282989_j_cclm-2026-0509_ref_015","unstructured":"Harmonised, I. Tripartite guideline. In: International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use; 2006."},{"key":"2026081209035282989_j_cclm-2026-0509_ref_016","unstructured":"Working Group 1 of the Joint Committee for Guides in Metrology. Evaluation of measurement data\u00a0\u2013\u00a0guide to the expression of uncertainty in measurement (GUM); 1995. Available from: https:\/\/www.bipm.org\/documents\/20126\/2071204\/JCGM_100_2008_E.pdf\/cb0ef43f-baa5-11cf-3f85-4dcd86f77bd6 1 July 2024."},{"key":"2026081209035282989_j_cclm-2026-0509_ref_017","doi-asserted-by":"crossref","unstructured":"Taibon, J, Santner, T, Singh, N, Ibrahim, SC, Babitzki, G, K\u00f6ppl, D, et al.. An isotope dilution-liquid chromatography-tandem mass spectrometry (ID-LC-MS\/MS)-based candidate reference measurement procedure (RMP) for the quantification of aldosterone in human serum and plasma. Clin Chem Lab Med 2023;61:1902\u201316. https:\/\/doi.org\/10.1515\/cclm-2022-0996.","DOI":"10.1515\/cclm-2022-0996"},{"key":"2026081209035282989_j_cclm-2026-0509_ref_018","doi-asserted-by":"crossref","unstructured":"Matuszewski, BK, Constanzer, ML, Chavez-Eng, CM. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS\/MS. Anal Chem 2003;75:3019\u201330. https:\/\/doi.org\/10.1021\/ac020361s.","DOI":"10.1021\/ac020361s"},{"key":"2026081209035282989_j_cclm-2026-0509_ref_019","unstructured":"Schuetzenmeister, A, Dufey, FVCA. Variance component analysis. Available from: https:\/\/cran.r-project.org\/web\/packages\/VCA\/index.html [Accessed 15 Sep 2022]."},{"key":"2026081209035282989_j_cclm-2026-0509_ref_020","unstructured":"Analyse-it Software, Ltd. Analyse-it Software 5.9 for Microsoft Excel; 2026."}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2026-0509\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2026-0509\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T09:04:19Z","timestamp":1786525459000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2026-0509\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":20,"alternative-id":["10.1515\/cclm-2026-0509"],"URL":"https:\/\/doi.org\/10.1515\/cclm-2026-0509","relation":{},"ISSN":["1434-6621","1437-4331"],"issn-type":[{"value":"1434-6621","type":"print"},{"value":"1437-4331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]}}}